Next Article in Journal
Characterization of HGF/Met Signaling in Cell Lines Derived From Urothelial Carcinoma of the Bladder
Next Article in Special Issue
Exploring the Mechanisms of Gastrointestinal Cancer Development Using Deep Sequencing Analysis
Previous Article in Journal
Clinicopathologic Characteristics and Outcomes of Histiocytic and Dendritic Cell Neoplasms: The Moffitt Cancer Center Experience Over the Last Twenty Five Years
Article Menu

Export Article

Open AccessReview
Cancers 2014, 6(4), 2296-2312; doi:10.3390/cancers6042296

Next-Generation Sequencing in Clinical Oncology: Next Steps Towards Clinical Validation

1
The University of Queensland, UQ Centre for Clinical Research, Herston Qld 4029, Australia
2
The Australian Centre for Oral Oncology Research & Education, Brisbane Qld 4000, Australia
*
Author to whom correspondence should be addressed.
Received: 11 October 2014 / Revised: 7 November 2014 / Accepted: 10 November 2014 / Published: 18 November 2014
(This article belongs to the Special Issue Next Generation Sequencing Approaches in Cancer)
View Full-Text   |   Download PDF [433 KB, uploaded 19 November 2014]   |  

Abstract

Compelling evidence supports the transition of next generation sequencing (NGS) technology from a research environment into clinical practice. Before NGS technologies are fully adopted in the clinic, they should be thoroughly scrutinised for their potential as powerful diagnostic and prognostic tools. The importance placed on generating accurate NGS data, and consequently appropriate clinical interpretation, has stimulated much international discussion regarding the creation and implementation of strict guidelines and regulations for NGS clinical use. In the context of clinical oncology, NGS technologies are currently transitioning from a clinical research background into a setting where they will contribute significantly to individual patient cancer management. This paper explores the steps that have been taken, and those still required, for the transition of NGS into the clinical area, with particular emphasis placed on validation in the setting of clinical oncology. View Full-Text
Keywords: massively parallel sequencing; next generation sequencing; clinical oncology; validation massively parallel sequencing; next generation sequencing; clinical oncology; validation
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Bennett, N.C.; Farah, C.S. Next-Generation Sequencing in Clinical Oncology: Next Steps Towards Clinical Validation. Cancers 2014, 6, 2296-2312.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top